Outcome of Board Meeting held on November 06, 2026, approving the buyback of equity shares.

Medplus Health Services Limited November 06, 2026 Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (E), Mumbai 400 051 BSE Scrip code: 543427 NSE Symbol: MEDPLUS Subject: Outcome of Board Meeting held on November 06, 2026, approving the buyback of equity shares Dear Sir/Madam, Further to our intimation dated October 30, 2026 and in terms of Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors (the “Board”) of Company at its meeting held on November 6, 2026 has, considered and approved the proposal for buyback of fully paid up equity shares of the Company having a face value of ₹2/- (Indian Rupees Two only) each (“Equity Shares” and such buyback “Buyback”), from all shareholders/ beneficial owners of the Equity Shares of the Company (other than the promoters and persons in control of the Company), through the “open market” route, using mechanism for acquisition of shares through stock exchange, pursuant to Article 77 of the Articles of Association of the Company and in accordance with the Securities and Exchange Board of India (Buy- Back of Securities) Regulations, 2018, as amended (“SEBI Buyback Regulations”) and such other circulars or notifications issued by the Securities and Exchange Board of India (“SEBI”) and the applicable provisions of the Companies Act, 2013 and rules made thereunder, as amended from time to time, at a price not exceeding ₹750/- (Indian Rupees Seven Hundred and Fifty only) per Equity Share (“Maximum Buyback Price”), payable in cash, for an aggregate amount not exceeding ₹ 130.00 Crores/- (Indian Rupees One Hundred and Thirty Crores only) (“Maximum Buyback Size”) which represents 9.87% and 6.61% of the aggregate of the Company’s fully paid-up Equity Share capital and free reserves based on both the audited standalone and consolidated financial statements of the Company as at March 31, 2026, respectively (being the latest available audited standalone and consolidated financial statements of the Company), which is within the statutory limits of 15% of the total paid-up Equity Share capital and free reserves based on both standalone and consolidated financial statements of the Company as at March 31, 2026 in accordance with with Regulation 4(i) of the SEBI Buyback Regulations read with proviso to Regulation 5(i)(b) of the SEBI Buyback Regulations, excluding expenses to be incurred for the Buyback viz. brokerage, turnover charges, applicable taxes such as securities transaction tax, goods and service tax, stamp duty, any expenses incurred or to be incurred for the Buyback like filing fee payable to SEBI, advisors, legal fees, intermediary fees, public announcement publication expenses, printing, dispatch expenses and other incidental and related expenses. At the Maximum Buyback Size and the Maximum Buyback Price, the indicative number of Equity Shares to be bought back under the Buyback would be 17,33,333 (Seventeen Lakh Thirty-Three Thousand Three Hundred and Thirty-Three only) Equity Shares (“Buyback Shares”) (representing 1.44% of the total paid- up equity share capital of the Company as on date i.e. November 06, 2026 and is less than 25% of the 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com Medplus Health Services Limited existing paid-up equity capital of the Company). If the Equity Shares are bought back at a price below the Maximum Buyback Price, the actual number of Equity Shares bought back could exceed the indicative Buyback Shares (assuming full deployment of the Maximum Buyback Size) but will always be subject to the Maximum Buyback Size and shall not exceed 25% of the existing paid-up equity capital of the Company. The Company shall utilise at least 75% of the Maximum Buyback Size, i.e., ₹97,50,00,000/- (Indian Rupees Ninety-Seven Crores Fifty Lakh only) (“Minimum Buyback Size”) for the Buyback and based on the Minimum Buyback Size and the Maximum Buyback Price, the Company will purchase an indicative minimum of 13,00,000 (Thirteen Lakh) Equity Shares. The process, timelines and other requisite details of the Buyback shall be set out in the public announcement, in accordance with the Buyback Regulations. The Board has constituted a committee called ‘Buyback Committee’ and delegated its powers to do such acts, deeds, matters, and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in relation to the proposed Buyback. The Board has appointed Mr. Shrenik Soni, Company Secretary and Compliance Officer of the Company as the compliance officer for the purposes of the proposed Buyback. The Board has appointed Nuvama Wealth Management Limited, as the Manager to the Buyback. The promoters and persons in control of the Company cannot participate in the Buyback through open market as per the SEBI Buyback Regulations. The details required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 are enclosed as Annexure-A. The Pre-Buyback and Post- Buyback shareholding pattern of the Company, is enclosed as Annexure B. The meeting of the Board of Directors commenced at 10:30 A.M. and concluded at 12:30 P.M. We request you to take the above information on record. Thanking You, Yours faithfully For Medplus Health Services Limited Shrenik Soni Company Secretary & Compliance Officer ICSI M.No.: F12400 Enclosures: As above 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com Medplus Health Services Limited ANNEXURE A Information required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular dated January 30, 2026 Details in relation to Buyback Sr. No Particulars Details 1. Number of securities proposed for Considering the Maximum Buyback Size and Maximum the Buyback Buyback Price, buyback of indicative number of 17,33,333 (Seventeen Lakh Thirty-Three Thousand Three Hundred and Thirty-Three only) Equity Shares. If the Equity Shares are bought back at a price lower than the Maximum Buy- back Price, then the actual number of Equity Shares bought back will exceed the indicative number of Equity Shares proposed to be bought back. 2. Number of securities proposed for Considering the Maximum Buyback Size and Maximum the Buyback as a percentage of Buyback Price, buyback of indicative number of 17,33,333 existing paid up capital (Seventeen Lakh Thirty-Three Thousand Three Hundred and Thirty-Three only) Equity Shares representing 1.44% of the total number of Equity Shares in the existing total paid-up Equity Share capital of the Company. However, the actual number of equity shares and percentage of existing paid-up capital bought back shall be ascertained following completion of the Buyback. 3. Buyback price Maximum Buyback Price of ₹750/- (Indian Rupees Seven Hundred and Fifty only) per Equity Share, payable in cash, for an amount aggregating up to ₹ 130.00 Crores/- (Indian Rupees One Hundred and Thirty Crores only) 4. Actual securities in number and Buyback of 17,33,333 (Seventeen Lakh Thirty-Three percentage of existing paid up capital Thousand Three Hundred and Thirty-Three only) Equity bought back Shares aggregating 1.44% of the total number of Equity Shares in the existing total paid-up Equity Share capital of the Company as on date of the board meeting i.e. November 06, 2026. However, the actual number of equity shares and percentage of existing [Showing first 8,000 characters — download PDF for full document]